Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs

Dow Jones

2025/07/25

By Colin Kellaher

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Bristol Myers on Friday said Cristian Massacesi, most recently chief medical officer and oncology chief development officer at AstraZeneca, will succeed Hirawat as executive vice president, chief medical officer and head of development on Aug. 1.

The Princeton, N.J., company said Hirawat, who joined as chief medical officer in 2019, will remain as an adviser through Nov. 1 to assist with the transition.

Bristol Myers said Massacesi will oversee its early- and late-stage product development across all therapeutic areas.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 25, 2025 07:30 ET (11:30 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554767695"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554767695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554767695?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554767695","market":"fut","top_or_hot":-1,"title":"Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Bristol <a href=\"https://laohu8.com/S/MYE\">Myers</a> Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities. \n</p>\n<p>\n  Bristol Myers on Friday said Cristian Massacesi, most recently chief medical officer and oncology chief development officer at AstraZeneca, will succeed Hirawat as executive vice president, chief medical officer and head of development on Aug. 1. \n</p>\n<p>\n  The Princeton, N.J., company said Hirawat, who joined as chief medical officer in 2019, will remain as an adviser through Nov. 1 to assist with the transition. \n</p>\n<p>\n  Bristol Myers said Massacesi will oversee its early- and late-stage product development across all therapeutic areas. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-25 19:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Bristol <a href=\"https://laohu8.com/S/MYE\">Myers</a> Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities. \n</p>\n<p>\n  Bristol Myers on Friday said Cristian Massacesi, most recently chief medical officer and oncology chief development officer at AstraZeneca, will succeed Hirawat as executive vice president, chief medical officer and head of development on Aug. 1. \n</p>\n<p>\n  The Princeton, N.J., company said Hirawat, who joined as chief medical officer in 2019, will remain as an adviser through Nov. 1 to assist with the transition. \n</p>\n<p>\n  Bristol Myers said Massacesi will oversee its early- and late-stage product development across all therapeutic areas. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施貴寶","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2554767695","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554767695","pubTimestamp":1753443000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.Bristol Myers on Friday said Cristian Massacesi, most recently chief medical officer and oncology chief development officer at AstraZeneca, will succeed Hirawat as executive vice president, chief medical officer and head of development on Aug. 1.The Princeton, N.J., company said Hirawat, who joined as chief medical officer in 2019, will remain as an adviser through Nov. 1 to assist with the transition.Bristol Myers said Massacesi will oversee its early- and late-stage product development across all therapeutic areas.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝","BK4126":"金属与玻璃容器","MYE":"Myers Industries Inc"},"translate_title":"Hirawat离职后，百时美施贵宝任命Massacesi为首席医疗官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1,"BMY":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities. \n\n\n  Bristol Myers on Friday said Cristian Massacesi, most recently chief medical officer and oncology chief development officer at AstraZeneca, will succeed Hirawat as executive vice president, chief medical officer and head of development on Aug. 1. \n\n\n  The Princeton, N.J., company said Hirawat, who joined as chief medical officer in 2019, will remain as an adviser through Nov. 1 to assist with the transition. \n\n\n  Bristol Myers said Massacesi will oversee its early- and late-stage product development across all therapeutic areas. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 25, 2025 07:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}